Sep. 8 at 12:43 AM
$NVAX 🚨New publication: Vaccine
Volume 92, 24 October 2026, 129034:
“The platform trial in COVID-19 priming and BOOsting (PICOBOO): The reactogenicity of nine licensed COVID-19 vaccines delivered in immunocompetent adults”.
🟡 One of the key findings: Reactogenicity was consistently lowest after Nuvaxovid compared to mRNA vaccines.
$SNY $PFE $MRNA
https://www.sciencedirect.com/science/article/abs/pii/S0264410X26008431?via%3Dihub